These are 53 projects, of which 85% are implemented by Greek companies.
It is in full development investment planning of the domestic drug industryafter the approval of 53 investments amounting to 519.28 million euros in the framework of the action “Reform the clawback system & offset it with research and investment costs“, of the National Recovery and Resilience Plan “Greece 2.0”. These 53 projects meet all the participation conditions and eligibility conditions, while 85% of them are implemented by Greek companies. The above projects are part of the dynamic plan of the Greek pharmaceutical industry for investments totaling 1.2 billion euros over four yearsthe Panhellenic Pharmaceutical Industry Association (PEF) states in its announcement.
“These investments have a unique multiplier effect on the economy, through the creation of added value that stays and is reinvested in the country. In addition, through these investments, Greece’s trade deficit is reduced, as it ensures that needs are met by domestic pharmaceutical production, while at the same time employment is boosted with permanent, skilled and well-paid new jobs“, emphasizes the (PEF).
He notes that with the completion of the investment program, Greece will be able to emerge as a European “hub” of production, research and innovation, while weaning off drug imports from third countries, such as China and Asia, will be completed. At the same time, domestic production will be further strengthened and exports abroad will increase, thus contributing to the reduction of the trade deficit.
Commenting on the approval of the 53 investments under the National Recovery and Resilience Plan “Greece 2.0”, the president of the Panhellenic Pharmaceutical Industry Union Theodoros Tryphon stated:
“The Greek pharmaceutical industry is actively participating in the effort to recover the national economy. With the help of the three co-competent ministries and in the context of offsetting the clawback with the sector’s productive investments, investments are implemented that have multiplier benefits for society. In particular, they protect the health and pharmaceutical care system, ensuring the adequacy of the market and patient access to any necessary treatment, reducing the dependence on imports, while at the same time they will lead to the emergence of our country as a hub for research and production of medicines in the wider region of SE Europe».
RES-EMP
Read the News today and get the latest news.
Follow Skai.gr on Google News and be the first to know all the news.
